GENITOURINARY CANCER—KIDNEY AND BLADDER

IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).Read more...

Related Posts

A chemical biology/modular antibody platform for ADP-ri...

 15

GASTROINTESTINAL CANCER—COLORECTAL AND ANAL

 28

DEVELOPMENTAL THERAPEUTICS—MOLECULARLY TARGETED AGENTS ...

 49